Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniela Rogoff

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
The New England Journal of Medicine|November 18, 2024
Oral Infigratinib Therapy in Children with AchondroplasiaRavi Savarirayan, Josep Maria De Bergua, Paul Arundel, et al.
Therapeutic Advances in Musculoskeletal Disease|March 28, 2022
Infigratinib in children with achondroplasia: the PROPEL and PROPEL 2 studiesRavi Savarirayan, Josep Maria De Bergua, Paul Arundel, et al.
The New England Journal of Medicine|June 29, 2026
Phase 3 Trial of Oral Infigratinib in Children with AchondroplasiaRavi Savarirayan, Julie Hoover-Fong, Melita Irving, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
The New England Journal of Medicine|November 18, 2024
Oral Infigratinib Therapy in Children with AchondroplasiaRavi Savarirayan, Josep Maria De Bergua, Paul Arundel, et al.
Therapeutic Advances in Musculoskeletal Disease|March 28, 2022
Infigratinib in children with achondroplasia: the PROPEL and PROPEL 2 studiesRavi Savarirayan, Josep Maria De Bergua, Paul Arundel, et al.
The New England Journal of Medicine|June 29, 2026
Phase 3 Trial of Oral Infigratinib in Children with AchondroplasiaRavi Savarirayan, Julie Hoover-Fong, Melita Irving, et al.
Pageof 2